Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Oncopeptides AB ( (SE:ONCO) ) is now available.
Oncopeptides AB reported a change in its share and vote structure following the completion of a recent rights issue that closed on March 16, 2026. The total number of shares has risen to 395,287,003, including 381,148,118 ordinary shares and 14,138,885 class C shares, while total voting rights now amount to 382,562,006.5.
As a result of the transaction, the company’s share capital increased by SEK 13,620,072.330911 to SEK 43,920,779.894805, reflecting a material strengthening of its equity base. This expanded capital structure provides Oncopeptides with additional financial flexibility to advance its oncology pipeline and support the commercialization of its flagship cancer therapy in Europe and other partnered regions.
The rights issue and resulting share increase may also impact existing shareholders through dilution, but it underscores continued investor support for the company’s development plans. With an enhanced capital position and a growing geographic footprint, Oncopeptides is better positioned to compete in the targeted cancer therapy market and progress its research programs in difficult-to-treat hematological diseases.
The most recent analyst rating on (SE:ONCO) stock is a Hold with a SEK3.00 price target. To see the full list of analyst forecasts on Oncopeptides AB stock, see the SE:ONCO Stock Forecast page.
More about Oncopeptides AB
Oncopeptides AB is a Swedish biotechnology company specializing in targeted therapies for difficult-to-treat cancers, with a particular focus on hematological malignancies. The company leverages its proprietary Peptide Drug Conjugate and SPiKE platforms to develop cytotoxic compounds, and its flagship cancer drug is being commercialized in Europe alongside partnership agreements in South Korea, the Middle East, Africa and other markets. Founded in 2000, Oncopeptides employs about 80 people and operates in Sweden, Germany, Austria, Spain and Italy, and its shares are listed on Nasdaq Stockholm under the ticker ONCO.
Average Trading Volume: 2,842,806
Technical Sentiment Signal: Sell
Current Market Cap: SEK536.8M
See more insights into ONCO stock on TipRanks’ Stock Analysis page.